Pub. Date : 2013 Feb
PMID : 23372106
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Five currently available BCR-ABL inhibitors form the mainstay of CML treatment, including first-generation imatinib and more potent second-generation BCR-ABL inhibitors dasatinib and nilotinib, with bosutinib and ponatinib having been recently approved for market inclusion. | Dasatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 2 | Five currently available BCR-ABL inhibitors form the mainstay of CML treatment, including first-generation imatinib and more potent second-generation BCR-ABL inhibitors dasatinib and nilotinib, with bosutinib and ponatinib having been recently approved for market inclusion. | Dasatinib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |